TRMT112 Antibody #57540
- WB
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 15 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
The TRMT11-TRMT112 complex deposits 2-methylguanosine at position 10 of tRNA, while ALKBH8-TRMT112 modifies a uridine at position 34 of the anti-codon loop (5,7) Additionally, TRMT112 plays a role in translation termination by interacting with N6AMT1, causing methylation of the release factor eRF1 to allow for stop codon recognition (8,9).
TRMT112 also contributes to ribosome biogenesis by interacting with and stabilizing WBSCR22, an 18s rRNA methyltransferase, and METTL5, the 18s rRNA m6a-methyltransferase (3,4,10).
- Songe-Møller, L. et al. (2010) Mol Cell Biol 30, 1814-27.
- Figaro, S. et al. (2008) FEBS Lett 582, 2352-6.
- van Tran, N. et al. (2019) Nucleic Acids Res 47, 7719-7733.
- Õunap, K. et al. (2015) PLoS One 10, e0133841.
- Purushothaman, S.K. et al. (2005) Mol Cell Biol 25, 4359-70.
- Gu, T. et al. (2012) Acta Histochem Cytochem 45, 113-9.
- Mazauric, M.H. et al. (2010) J Biol Chem 285, 18505-15.
- Pachman, L.M. et al. (2006) Arthritis Rheum 54, 3345-50.
- Heurgué-Hamard, V. et al. (2005) J Biol Chem 280, 2439-45.
- Zorbas, C. et al. (2015) Mol Biol Cell 26, 2080-95.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.